Abstract

Based on network pharmacology and molecular docking techniques and methods, to explore the active components and potential effects of Drynaria fortunei combined with platelet-rich plasma intervention therapy on fracture healing diseases. The gene cards database, the human Mendelian genetic database, Online Mendelian Inheritance in Man database, and the DisGeNET database were searched to identify fracture-related targets. Then, the active chemical components and targets in Rhizoma Drynariae were screened through the traditional Chinese medicine systematic pharmacology and analysis platform database. Then, the characteristic genes of platelet-rich plasma were searched through the GSE203196, and the common targets of drugs and diseases were screened through R language. Construct a drug candidate compound target network diagram. Use the protein interaction network function enrichment analysis database and the Cytoscape software to build a protein interaction network, use AutoDock Vina for analysis and docking, use R language to conduct Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis on the critical targets of the fracture of the combination of Drynaria fortunei and platelet-rich plasma intervention therapy, and determine the core target and mechanism of the variety of Drynaria fortunei and platelet-rich plasma treatment of the fracture. A total of 18 active compounds were obtained from Rhizoma Drynariae. There are 18 overlapping targets of Drynaria and platelet-rich plasma fracture. There are 13 active ingredients related to disease targets. Rhizoma Drynariae and platelet-rich plasma are mainly involved in regulating prostaglandin-endoperoxide synthase 2, androgen receptor, caspase-2, and B-cell lymphoma 2 to play a role in treating fractures. The treatment of fracture with Drynaria fortunei combined with platelet-rich plasma is a complex process of multi-components, multi-targets, and multi-pathways related to the coordinated regulation of multiple targets and signal pathways.